VRPX vs. MBIO, EVOK, GOVX, PHAS, REVB, HILS, ENSC, PHIO, SNGX, and BCEL
Should you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include Mustang Bio (MBIO), Evoke Pharma (EVOK), GeoVax Labs (GOVX), PhaseBio Pharmaceuticals (PHAS), Revelation Biosciences (REVB), Hillstream BioPharma (HILS), Ensysce Biosciences (ENSC), Phio Pharmaceuticals (PHIO), Soligenix (SNGX), and Atreca (BCEL). These companies are all part of the "pharmaceutical preparations" industry.
Virpax Pharmaceuticals (NASDAQ:VRPX) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, community ranking, earnings, risk, media sentiment, analyst recommendations and institutional ownership.
Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Virpax Pharmaceuticals and Virpax Pharmaceuticals both had 2 articles in the media. Virpax Pharmaceuticals' average media sentiment score of 1.22 beat Mustang Bio's score of 0.86 indicating that Virpax Pharmaceuticals is being referred to more favorably in the media.
Mustang Bio has a consensus target price of $17.25, indicating a potential upside of 5,125.69%. Given Mustang Bio's higher possible upside, analysts clearly believe Mustang Bio is more favorable than Virpax Pharmaceuticals.
Mustang Bio received 166 more outperform votes than Virpax Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Virpax Pharmaceuticals an outperform vote while only 64.12% of users gave Mustang Bio an outperform vote.
Virpax Pharmaceuticals' return on equity of -169.04% beat Mustang Bio's return on equity.
32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.0% of Mustang Bio shares are owned by institutional investors. 6.2% of Virpax Pharmaceuticals shares are owned by company insiders. Comparatively, 2.1% of Mustang Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Virpax Pharmaceuticals has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.
Summary
Virpax Pharmaceuticals beats Mustang Bio on 7 of the 13 factors compared between the two stocks.
Get Virpax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Virpax Pharmaceuticals Competitors List
Related Companies and Tools
